Free Submission Public Relations &
Deutsch English


Ulcerative Colitis - Pipeline Review, H1 2013: New research report available at Fast Market Research

Print article Print article
2013-04-04 18:15:54 - Fast Market Research recommends "Ulcerative Colitis - Pipeline Review, H1 2013" from Global Markets Direct, now available

Global Markets Direct's, 'Ulcerative Colitis - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Ulcerative Colitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ulcerative Colitis. Ulcerative Colitis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated



* A snapshot of the global therapeutic scenario for Ulcerative Colitis.
* A review of the Ulcerative Colitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Ulcerative Colitis pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Full Report Details at
- ..

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Ulcerative Colitis.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Ulcerative Colitis pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Global Markets Direct Report Coverage
Ulcerative Colitis Overview
Therapeutics Development
An Overview of Pipeline Products for Ulcerative Colitis
Ulcerative Colitis Therapeutics under Development by Companies
Ulcerative Colitis Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Ulcerative Colitis Therapeutics - Products under Development by Companies
Ulcerative Colitis Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Ulcerative Colitis Therapeutics Development
Bristol-Myers Squibb Company
Johnson & Johnson
Biogen Idec Inc.
Amgen Inc.
AstraZeneca PLC
Athersys, Inc.
GlaxoSmithKline plc
Genentech, Inc.
MedImmune LLC
Euroscreen S.A.
Novo Nordisk A/S
Takeda Pharmaceutical Company Limited
BioLineRx, Ltd.
Celltrion, Inc.
Axcan Pharma Inc.
Pfizer Inc.
Zeria Pharmaceutical Co Ltd
GW Pharmaceuticals plc
iCo Therapeutics Inc.
Karo Bio
Ore Pharmaceuticals Inc
Cosmo Pharmaceuticals S.p.A
Lexicon Pharmaceuticals, Inc.
Pluristem Therapeutics Inc.
LTT Bio-Pharma Co., Ltd.
Proximagen Neuroscience plc.
InDex Pharmaceuticals AB
Am-Pharma B.V.
Palau Pharma S.A
Farmacija d.o.o. Tuzla
Tillotts Pharma AG
Coronado Biosciences, Inc.
Alloksys Life Sciences BV
Vascular Biogenics Ltd.
Txcell SA
TcL Pharma SAS
Avaxia Biologics, Inc.
Drais Pharmaceuticals, Inc.
Giuliani S.p.A.
KYORIN Pharmaceutical Co., Ltd.
Synergy Pharmaceuticals, Inc.
Medestea Research & Production S.p.A.
NasVax Ltd.
Dr. Falk Pharma GmbH
Receptos, Inc.
Altheus Therapeutics, Inc.
AesRx, LLC.
Atlantic Healthcare Limited
Immune Technologies and Medicine
Sigmoid Pharma.
Ulcerative Colitis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
mesalamine - Drug Profile
etrolizumab - Drug Profile
ASP-3291 - Drug Profile
tofacitinib - Drug Profile
tralokinumab - Drug Profile
eldelumab - Drug Profile
MultiStem - Drug Profile
GSK-1399686 - Drug Profile
telotristat etiprate - Drug Profile
DIMS-0150 - Drug Profile
dersalazine - Drug Profile
vedolizumab - Drug Profile
vedolizumab - Drug Profile
budesonide - Drug Profile
adalimumab - Drug Profile
interferon beta-1a - Drug Profile
vidofludimus - Drug Profile
PC-SOD - Drug Profile
ORE-1001 - Drug Profile
VB-201 - Drug Profile
OvaSave - Drug Profile
MD-707 - Drug Profile
infliximab - Drug Profile
anrukinzumab - Drug Profile
LT-02 - Drug Profile
KRP-203 - Drug Profile
budesonide - Drug Profile
bertilimumab - Drug Profile
catridecacog - Drug Profile
mesalamine - Drug Profile

Full Table of Contents is available at:

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

Bill Thompson
Phone: 18008448156

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News


Terms & Conditions | Privacy | About us | Contact